Leap Therapeutics Inc (OQ:LPTX)

Business Focus: Bio Therapeutic Drugs

Feb 05, 2019 12:29 ET
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock, as well as an additional 985,714 shares of its common stock and warrants to purchase up to 985,714 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional securities. Total gross proceeds to Leap...
Feb 01, 2019 08:28 ET
Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Feb. 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined offering price of $1.75 per share and accompanying warrant. The warrants will be exercisable commencing on the date of issuance, wil...
Jan 29, 2019 08:10 ET
Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Match Group, Inc. (NASDAQ:MTCH), Antero Resources Corporation...
Jan 14, 2019 06:00 ET
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
CAMBRIDGE, Mass., Jan. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01, as a monotherapy and in combination with docetaxel in patients with advanced prostate cancer. This clinical trial is specifically targeting a biomarker-selected patient population in metastatic castration-resistant prostate cancer (mCRPC) with elevated Dickkopf-1 (DKK1) levels....
Dec 14, 2018 06:00 ET
Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
CAMBRIDGE, Mass., Dec. 14, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of TRX518 in combination with gemcitabine, KeytrudaÒ (pembrolizumab), or OpdivoÒ (nivolumab) in patients with advanced solid tumors at the European Society for Molecular Oncology (ESMO) Immuno-Oncology Congress 2018.  In addition, Leap provided the top-line final data from the Phase I/II study of DKN-01 in combination with gemcitabine and cisplatin chemotherapy in patients with advanced biliary tract cancer....
Nov 09, 2018 06:05 ET
Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the third quarter ended September 30, 2018. ...
Nov 09, 2018 06:00 ET
Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with paclitaxel in patients with advanced esophagogastric cancer at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting (SITC 2018)....
Oct 21, 2018 06:45 ET
Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress
CAMBRIDGE, Mass., Oct. 21, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with Keytruda® (pembrolizumab) in patients with advanced esophagogastric cancer at the European Society for Molecular Oncology (ESMO) 2018 Annual Congress....
Oct 17, 2018 09:00 ET
Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Fitbit, Inc. (NYSE:FIT),...
Oct 08, 2018 18:35 ET
Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress
CAMBRIDGE, Mass., Oct. 8, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that data from the study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced gastroesophageal cancer will be presented in a poster presentation at the European Society of Medical Oncology (ESMO) 2018 Annual Congress, taking  place October 19-23, 2018 in Munich, Germany. The abstract was published online in advance of the poster presentation that will include additional patient data as...
Sep 25, 2018 07:00 ET
Leap Therapeutics to Present at Two October Conferences
CAMBRIDGE, Mass., Sept. 25, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the following investor conferences: ...
Aug 30, 2018 16:05 ET
Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference
CAMBRIDGE, Mass., Aug. 30, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held in New York City on September 4-6, 2018....
Aug 22, 2018 07:40 ET
Recent Analysis Shows Leap Therapeutics, Gardner Denver, Medical Transcription Billing, CarGurus, Liberty Media, and Quorum Health Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leap Therapeutics, Inc. (NASDAQ:LPTX), Gardner Denver Holdings, Inc....
Aug 08, 2018 07:00 ET
Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second quarter ended June 30, 2018. “Over the past few months, we...
Jul 23, 2018 07:30 ET
Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate Leap’s...
Jun 13, 2018 07:55 ET
Analysis: Positioning to Benefit within Ruth's Hospitality Group, S&P Global, Shaw Communications, Leap Therapeutics, Red Hat, and Welltower — Research Highlights Growth, Revenue, and Consolidated Res
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ruth's Hospitality Group, Inc. (NASDAQ:RUTH), S Global Inc. (NYSE:SPGI),...
Jun 13, 2018 07:00 ET
Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate...
May 11, 2018 07:00 ET
Leap Therapeutics Reports First Quarter 2018 Financial Results
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2018. “We had a strong first quarter, as we presented data...
Apr 16, 2018 09:00 ET
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The presentation highlighted...
Mar 28, 2018 08:00 ET
New Research Coverage Highlights Holly Energy Partners, Liberty Property Trust, Fair Isaac, 58, Cousins Properties, and Leap Therapeutics — Consolidated Revenues, Company Growth, and Expectations for
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P. (NYSE:HEP), Liberty...
Mar 27, 2018 16:05 ET
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 2,146,667 shares of its common stock, which...
Mar 23, 2018 09:00 ET
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 1,866,667 shares of its common stock...
Mar 22, 2018 16:05 ET
Leap Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All shares...
Mar 21, 2018 07:00 ET
Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview...
Mar 14, 2018 17:00 ET
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in...
Mar 07, 2018 07:00 ET
Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview...
Feb 23, 2018 07:00 ET
Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders
CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2017. Leap additionally announced that...
Feb 06, 2018 07:00 ET
Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 20th Annual...
Jan 16, 2018 07:00 ET
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating Leap’s GITR...
Nov 15, 2017 07:00 ET
Leap Therapeutics Announces $18 Million Private Placement Offering
CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a purchase agreement to issue and sell shares of its common stock...
Nov 13, 2017 07:00 ET
Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2017. Leap additionally announced that the first...
Aug 11, 2017 07:00 ET
Leap Therapeutics Reports Second Quarter 2017 Financial Results
CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2017....
May 17, 2017 17:16 ET
Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data from the Phase 1 study of DKN-01 in combination with standard of care chemotherapy in patients with advanced biliary tract cancers. Data from the study was published online as an abstract in advance of a poster presentation being held at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 - 6, 2017 in Chicago, Illinois.  ...
Mar 31, 2017 16:36 ET
Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data....
Mar 01, 2017 18:39 ET
Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced preclinical and clinical data presentations will be made during the 2017 American Association for Cancer Research (AACR) Annual Meeting, being held April 1 - 5, 2017, in Washington, D.C. Data on TRX518 will be presented as an oral presentation in a clinical trials plenary session by Roberta Zappasodi, Ph.D., Parker Institute Scholar and Research Scholar in the Ludwig Collaborative Laboratory at Memorial Slo...